(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip code) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Exhibit Number | Description | |||||||
104 | Cover page Interactive Data File (embedded with the Inline XBRL document) |
NAUTILUS BIOTECHNOLOGY, INC. | ||||||||
By: | /s/ Sujal Patel | |||||||
Name: | Sujal Patel | |||||||
Title: | Chief Executive Officer |
Nautilus Biotechnology, Inc. Condensed Consolidated Balance Sheets As of March 31, 2023 and December 31, 2022 (Unaudited) |
(in thousands, except share and per share amounts) | March 31, 2023 | December 31, 2022 | |||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 88,505 | $ | 114,523 | |||||||
Short-term investments | 78,843 | 69,948 | |||||||||
Prepaid expenses and other current assets | 3,136 | 2,738 | |||||||||
Total current assets | 170,484 | 187,209 | |||||||||
Property and equipment, net | 3,948 | 3,700 | |||||||||
Operating lease right-of-use assets | 35,703 | 28,866 | |||||||||
Long-term investments | 134,641 | 129,169 | |||||||||
Other long-term assets | 1,108 | 1,108 | |||||||||
Total assets | $ | 345,884 | $ | 350,052 | |||||||
Liabilities and Stockholders’ Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 1,266 | $ | 1,272 | |||||||
Accrued expenses and other liabilities | 3,593 | 3,528 | |||||||||
Current portion of operating lease liability | 3,070 | 1,991 | |||||||||
Total current liabilities | 7,929 | 6,791 | |||||||||
Operating lease liability, net of current portion | 34,240 | 28,337 | |||||||||
Total liabilities | 42,169 | 35,128 | |||||||||
Stockholders’ equity: | |||||||||||
Preferred stock | — | — | |||||||||
Common stock | 12 | 12 | |||||||||
Additional paid-in capital | 458,191 | 455,330 | |||||||||
Accumulated other comprehensive loss | (959) | (1,854) | |||||||||
Accumulated deficit | (153,529) | (138,564) | |||||||||
Total stockholders’ equity | 303,715 | 314,924 | |||||||||
Total liabilities and stockholders’ equity | $ | 345,884 | $ | 350,052 |
Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Operations Three Months Ended March 31, 2023 and 2022 (Unaudited) |
Three months ended March 31, | |||||||||||
(in thousands, except share and per share amounts) | 2023 | 2022 | |||||||||
Operating expenses | |||||||||||
Research and development | $ | 10,877 | $ | 9,658 | |||||||
General and administrative | 7,183 | 6,364 | |||||||||
Total operating expenses | 18,060 | 16,022 | |||||||||
Other income (expense), net | 3,095 | 259 | |||||||||
Net loss | $ | (14,965) | $ | (15,763) | |||||||
Net loss per share attributable to common stockholders, basic and diluted | $ | (0.12) | $ | (0.13) | |||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 124,590,351 | 124,418,580 |
Nautilus Biotechnology, Inc. Condensed Consolidated Statements of Cash Flows Three Months Ended March 31, 2023 and 2022 (Unaudited) |
Three Months Ended March 31, | |||||||||||
(in thousands) | 2023 | 2022 | |||||||||
Cash flows from operating activities | |||||||||||
Net loss | $ | (14,965) | $ | (15,763) | |||||||
Adjustments to reconcile net loss to net cash used in operating activities | |||||||||||
Depreciation | 385 | 281 | |||||||||
Stock-based compensation | 2,860 | 2,110 | |||||||||
Amortization (accretion) of premium (discount) on securities, net | (669) | 26 | |||||||||
Amortization of operating lease right-of-use assets | 786 | 525 | |||||||||
Changes in operating assets and liabilities: | |||||||||||
Prepaid expenses and other assets | (513) | 554 | |||||||||
Accounts payable | 53 | (394) | |||||||||
Accrued expenses and other liabilities | 65 | 308 | |||||||||
Operating lease liabilities | (526) | 18 | |||||||||
Net cash used in operating activities | (12,524) | (12,335) | |||||||||
Cash flows from investing activities | |||||||||||
Proceeds from maturities of securities | 14,249 | 38,575 | |||||||||
Purchases of securities | (27,052) | (22,912) | |||||||||
Purchases of property and equipment | (692) | (481) | |||||||||
Net cash (used in) provided by investing activities | (13,495) | 15,182 | |||||||||
Cash flows from financing activities | |||||||||||
Proceeds from exercise of stock options | 1 | 156 | |||||||||
Net cash provided by financing activities | 1 | 156 | |||||||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (26,018) | 3,003 | |||||||||
Cash, cash equivalents and restricted cash at beginning of period | 115,477 | 186,461 | |||||||||
Cash, cash equivalents and restricted cash at end of period | $ | 89,459 | $ | 189,464 |
Cover |
May 02, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | May 02, 2023 |
Entity Registrant Name | NAUTILUS BIOTECHNOLOGY, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-39434 |
Entity Tax Identification Number | 98-1541723 |
Entity Address, Address Line One | 2701 Eastlake Avenue East |
Entity Address, City or Town | Seattle |
Entity Address, State or Province | WA |
Entity Address, Postal Zip Code | 98102 |
City Area Code | 206 |
Local Phone Number | 333-2001 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | NAUT |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001808805 |
Amendment Flag | false |
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end
R5?A4N]?6@ 2K@7,YP-U8<#_9O!$>+C\\U'UI@/M.-QC2>\,$[MT
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M?%/3]8;W7J[97A>BB9S%326,)=
MD[QY'+#+Y,,5(#/$-9-+[LDQRINNXED2JP=U^L!\F=J+12^UH'Z.G]PSZJ;9
MQ8>'X#Q#.WEPW*^Z[-=%:"__UNO6>_KZG_6Z,?WM0K:MVH<18''[SV>-LX7*
MXDMS_(,8\_P#"VJ7!B'&9R\RV\RG0$!?OZ$IWCGSXHBP71\!GVRL%9)E## S
M,72$/WZAC@S;[D:,A2O2O-SK-K>9>EF8-L]YMFCLUN_FW9G.W.Y_L;&,?^+.V
MTC$C,"GE[MNQ=9-))!N\Y"$\S-KLZ>2T.I=,5T0!UOGBVHV,HH.1#+S5^E+R
MERN9_VPBQ?+
H>Z@&X'69WC)/2_]
M[^TO@P5-.JLMMP/=%)I?@6%G8#A_&!CZIS#F2PE\9K!2*L"/\VF[60'?N3:K
M5S_[5I_U;/D2@,,>"&!P/4=EFD? >BF"]>( ,!B::F)-5CVBNX94U)3